151
|
Parrott AM, Shi J, Aaron J, Green DA, Whittier S, Wu F. Detection of multiple hypervirulent Klebsiella pneumoniae strains in a New York City hospital through screening of virulence genes. Clin Microbiol Infect 2020; 27:583-589. [PMID: 32461145 DOI: 10.1016/j.cmi.2020.05.012] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Revised: 05/09/2020] [Accepted: 05/13/2020] [Indexed: 12/28/2022]
Abstract
OBJECTIVES The 'hypervirulent' variant of Klebsiella pneumoniae (hvKp) is a predominant cause of community-acquired pyogenic liver abscess in Asia, and is an emerging pathogen in Western countries. hvKp infections have demonstrated 'metastatic' dissemination in immunocompetent hosts, an unusual mode of infection associated with severe complications. Two cases alerted us to the possible presence of hvKp at our hospital, both involving elderly Hispanic males who presented with recurrent fever, bacteraemia, epigastric pain and liver abscesses/phlegmon, thus prompting an assessment of hvKp prevalence. METHODS A surveillance of K. pneumoniae blood, body fluid and wound isolates was conducted using real-time PCR to detect virulence-associated genes (uni-rmpA, iucA and peg344). Positive isolates were further characterized by wzi gene sequencing to determine capsular types (K-type) and by multilocus sequence typing and pulsed-field gel electrophoresis to determine strain relatedness. RESULTS Four-hundred and sixty-three K. pneumoniae isolates, derived from 412 blood, 21 body fluids and 30 abdominal wound specimens, were screened over a 3-year period. Isolates included 98 multidrug-resistant strains. Eighteen isolates from 17 patients, including two from the index patient, screened positive for all three virulence genes. Sixteen of 18 positive isolates had K-types associated with hvKp, and isolates from different patients were unrelated strains, indicating likely community acquisition. Of 13 patients with significant morbidity, five died; eight patients had co-existing hepatobiliary disease, and six had diabetes mellitus. CONCLUSIONS Multiple strains of hvKp are emerging in New York City and are associated with high mortality relative to multidrug-resistant and classical Klebsiella infections. Co-existing hepatobiliary disease appears to be a potential risk factor for these infections.
Collapse
Affiliation(s)
- A M Parrott
- Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
| | - J Shi
- Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA
| | - J Aaron
- Department of Medicine, Division of Infectious Diseases, Columbia University Irving Medical Center, New York, NY, USA
| | - D A Green
- Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA
| | - S Whittier
- Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA
| | - F Wu
- Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA
| |
Collapse
|
152
|
Liu MM, Shi J. [Physiological and pathological effects of nitric oxide and nitric oxide synthase in oral cavity]. Zhonghua Kou Qiang Yi Xue Za Zhi 2020; 55:353-356. [PMID: 32392980 DOI: 10.3760/cma.j.cn112144-20190522-00214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Nitric oxide (NO) is a short-lived free radical which is not only involved in regulating many physiological processes of the body, but also closely related to many diseases. Nitric oxide synthase (NOS) is the key enzyme for NO production. NOS exists as three distinct isoforms, the endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). It has been found that nNOS and eNOS were expressed in normal pulp tissues, periodontal tissues and salivary glands, and the NO produced from nNOS and eNOS was involved in their physiological functions. NO and iNOS are involved in the occurrence and development of pulpitis, periodontitis, salivary gland disease and oral cancer. This review focuses on the physiological and pathological effects of NO and different subtypes of NOS in oral cavity.
Collapse
Affiliation(s)
- M M Liu
- Shanxi Medical University School and Hospital of Stomatology,Taiyuan 030001, China
| | - J Shi
- Department of Oral Medicine, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan 030012, China
| |
Collapse
|
153
|
Bai J, Shi J, Zhang S, Zhang C, Zhai Y, Wang S, Li M, Li C, Zhao P, Geng S, Gui S, Jing L, Zhang Y. MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas. AJNR Am J Neuroradiol 2020; 41:852-858. [PMID: 32381547 DOI: 10.3174/ajnr.a6557] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 03/08/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND AND PURPOSE MR imaging is a useful and widely used evaluation for chordomas. Prior studies have classified chordomas into cell-dense type and matrix-rich type according to the ultrastructural features. However, the relationship between the MR imaging signal intensity and ultrastructural classification is unknown. We hypothesized that MR imaging signal intensity may predict both tumor ultrastructural classification and prognosis. MATERIALS AND METHODS Seventy-nine patients with skull base chordomas who underwent 95 operations were included in this retrospective single-center series. Preoperative tumor-to-pons MR imaging signal intensity ratios were calculated and designated as ratio on T1 FLAIR sequence (RT1), ratio on T2 sequence (RT2), and ratio on enhanced T1 FLAIR sequence (REN), respectively. We assessed the relationships among signal intensity ratios, ultrastructural classification, and survival. RESULTS Compared with the matrix-rich type group, the cell-dense type chordomas showed lower RT2 (cell-dense type: 1.90 ± 0.38; matrix-rich type: 2.61 ± 0.60 P < .001). The model of predicting cell-dense type based on RT2 had an area under the curve of 0.83 (95% CI, 0.75-0.92). In patients without radiation therapy, both progression-free survival (P = .003) and overall survival (P = .002) were longer in the matrix-rich type group than in the cell-dense type group. REN was a risk factor for progression-free survival (hazard ratio = 10.24; 95% CI, 1.73-60.79); RT2 was a protective factor for overall survival (hazard ratio = 0.33; 95% CI, 0.12-0.87); and REN was a risk factor for overall survival (hazard ratio = 4.76; 95% CI, 1.51-15.01). CONCLUSIONS The difference in MR imaging signal intensity in chordomas can be explained by electron microscopic features. Both signal intensity ratios and electron microscopic features may be prognostic factors.
Collapse
Affiliation(s)
- J Bai
- From the Department of Neurosurgery (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Beijing Neurosurgical Institute (J.B., S.Z., C.Z., Y. Zhai, S.W., M.L., C.L., Y. Zhang), Capital Medical University, Beijing, China
- China National Clinical Research Center for Neurological Diseases (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing, China
| | - J Shi
- Department of Neurosurgery (J.S.), Tsinghua University Yuquan Hospital, Beijing, China
| | - S Zhang
- Beijing Neurosurgical Institute (J.B., S.Z., C.Z., Y. Zhai, S.W., M.L., C.L., Y. Zhang), Capital Medical University, Beijing, China
- Department of Neurosurgery (S.Z.), Anshan Central Hospital, Anshan, China
| | - C Zhang
- Beijing Neurosurgical Institute (J.B., S.Z., C.Z., Y. Zhai, S.W., M.L., C.L., Y. Zhang), Capital Medical University, Beijing, China
| | - Y Zhai
- Beijing Neurosurgical Institute (J.B., S.Z., C.Z., Y. Zhai, S.W., M.L., C.L., Y. Zhang), Capital Medical University, Beijing, China
- Department of Neurosurgery (Y. Zhai), First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
| | - S Wang
- Beijing Neurosurgical Institute (J.B., S.Z., C.Z., Y. Zhai, S.W., M.L., C.L., Y. Zhang), Capital Medical University, Beijing, China
| | - M Li
- Beijing Neurosurgical Institute (J.B., S.Z., C.Z., Y. Zhai, S.W., M.L., C.L., Y. Zhang), Capital Medical University, Beijing, China
| | - C Li
- Beijing Neurosurgical Institute (J.B., S.Z., C.Z., Y. Zhai, S.W., M.L., C.L., Y. Zhang), Capital Medical University, Beijing, China
| | - P Zhao
- From the Department of Neurosurgery (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- China National Clinical Research Center for Neurological Diseases (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing, China
| | - S Geng
- From the Department of Neurosurgery (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- China National Clinical Research Center for Neurological Diseases (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing, China
| | - S Gui
- From the Department of Neurosurgery (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- China National Clinical Research Center for Neurological Diseases (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing, China
| | - L Jing
- Department of Health Statistics (L.J.), Shanxi Medical University, Taiyuan, China
| | - Y Zhang
- From the Department of Neurosurgery (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Beijing Neurosurgical Institute (J.B., S.Z., C.Z., Y. Zhai, S.W., M.L., C.L., Y. Zhang), Capital Medical University, Beijing, China
- China National Clinical Research Center for Neurological Diseases (J.B., P.Z., S. Geng, S. Gui, Y. Zhang), Beijing, China
| |
Collapse
|
154
|
Zhang XJ, Cao G, Fu J, Zhuang HJ, Shi J. The role of hsa_circ_0000285 in metastasis of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2020; 24:3579-3585. [PMID: 32329832 DOI: 10.26355/eurrev_202004_20819] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The importance of circular RNAs in malignant tumors causes more attention in researchers. Hepatocellular carcinoma (HCC) is one of the most ordinary malignant tumors. Hsa_circ_0000285 was explored to identify how it functions in the metastasis of HCC. PATIENTS AND METHODS Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) was utilized to detect hsa_circ_0000285 expression in HCC patients' tissues. Hsa_circ_0000285 lentivirus and shRNA was constructed for the transfection of HCC cells. Wound healing assay, transwell assay, and Matrigel assay were conducted to identify the function of hsa_circ_0000285 in HCC cells. Furthermore, mechanism assays were performed to uncover the interaction between hsa_circ_0000285 and miR-599. RESULTS Hsa_circ_0000285 was significantly higher-expressed in HCC samples compared to that in adjacent samples. The migrated length of HCC cells was reduced after hsa_circ_0000285 was silenced, while the migrated length of HCC cells was increased after hsa_circ_0000285 was overexpressed. Moreover, the number of migrated and invaded HCC cells was reduced after hsa_circ_0000285 was silenced, while the number of migrated and invaded HCC cells was increased after hsa_circ_0000285 was overexpressed. Moreover, RT-qPCR results revealed that miR-599 was downregulated via overexpression of hsa_circ_0000285, while miR-599 was upregulated via knockdown of hsa_circ_0000285. Further experiments showed that miR-599 was a direct target of hsa_circ_0000285 in HCC. CONCLUSIONS Hsa_circ_0000285 could enhance cell metastasis of HCC by targeting miR-599 and might be a potential therapeutic target in HCC.
Collapse
Affiliation(s)
- X-J Zhang
- Department of Hepatobiliary Surgery, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, China.
| | | | | | | | | |
Collapse
|
155
|
Wilde D, Castro P, Haugen A, Shi J, Lai S, Chiao E, Hernandez D, Sikora A, Sandulache V. The Evolution of Intermediate Risk Oropharyngeal Cancer in a Veteran Population: a 15 Year Study. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
156
|
Shen X, Shi J, Xu L, Meng HX. [Influential factors related to the long-term effect of periodontal-orthodontic treatment in patients with aggressive periodontitis and malocclusion]. Zhonghua Kou Qiang Yi Xue Za Zhi 2020; 55:86-92. [PMID: 32074668 DOI: 10.3760/cma.j.issn.1002-0098.2020.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the influential factors related to the long-term effect of periodontal-orthodontic treatment in patients with aggressive periodontitis (AgP). Methods: A retrospective analysis was conducted in 25 AgP patients, who have received periodontal-orthodontic treatment in Peking University School and Hospital of Stomatology. Changes in the ratio of the residual alveolar bone height (RBH) was measured at three time points: baseline (T0), post orthodontic treatment (T1), and the last re-visit 3 years after orthodontic treatment (T2). Root abnormity was evaluated by observing periapical radiographs, and its relationship with alveolar bone loss after orthodontic treatment was analyzed. A multi-level analysis on factors related to the clinical outcome (alveolar bone height change) was performed. Results: Totally 693 teeth of 25 patients at T0 and T1 and 368 teeth of 14 patients at T2 were investigated. During the periodontal-orthodontic treatment, the RBH was mainly influenced by root abnormity (estimation value -2.392), tooth position (estimation value for upper teeth vs. lower teeth 3.139, and anterior teeth vs. posterior teeth -3.469) and the baseline RBH at T0 (estimation value -0.391) (P<0.05). Teeth with root abnormity, teeth in mandibular and anterior area, and teeth with higher RBH showed less change in T1-T0 RBH values. In the long-term follow-up, RBH was mainly influenced by tooth position (estimation value for upper teeth vs. lower teeth 3.735, and anterior teeth vs. posterior teeth -5.318), the baseline RBH and probing depth (PD) at T0. Teeth in mandibular and anterior area, teeth with higher RBH (estimation value -0.498) and PD (estimation value -1.594) (P<0.05) showed less change in T0-T2 RBH values. Conclusions: During orthodontic treatment, teeth with abnormal root, lower teeth, anterior teeth, and teeth with high RBH were unfavorable factors for bone gain. In the long-term observation, lower teeth, anterior teeth, teeth with high RBH and PD at first visit were unfavorable factors for bone gain.
Collapse
Affiliation(s)
- X Shen
- Center of Stomatology, China-Japan Friendship Hospital, Beijing 100029, China
| | - J Shi
- Department of Orthodontics, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
| | - L Xu
- Department of Periodontology, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
| | - H X Meng
- Department of Periodontology, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
| |
Collapse
|
157
|
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Meco C, Matricardi PM, O'Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kawauchi H, Kjeldsen A, Klimek L, Krzeski A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdjoubi A, Mesbahi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Orlandi R, Otori N, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raftopulos M, Rombaux P, Riechelmann H, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Sindvongs K, Soklic Kosak T, Stjarne P, Sutikno B, Steinsvag S, Tantilipikorn P, Thanaviratananich S, Tran T, Urbancic J, Valiulius A, Vasquez de Aparicio C, Vicheva D, Virkkula PM, Vicente G, Voegels R, Wagenmann MM, Wardani RS, Welge-Lussen A, Witterick I, Wright E, Zabolotniy D, Zsolt B, Zwetsloot CP. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58:1-464. [PMID: 32077450 DOI: 10.4193/rhin20.600] [Citation(s) in RCA: 521] [Impact Index Per Article: 130.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 such as paediatric CRS and sinus surgery. EPOS2020 also involves new stakeholders, including pharmacists and patients, and addresses new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestions for future research in this area and offers updated guidance for definitions and outcome measurements in research in different settings. EPOS2020 contains chapters on definitions and classification where we have defined a large number of terms and indicated preferred terms. A new classification of CRS into primary and secondary CRS and further division into localized and diffuse disease, based on anatomic distribution is proposed. There are extensive chapters on epidemiology and predisposing factors, inflammatory mechanisms, (differential) diagnosis of facial pain, allergic rhinitis, genetics, cystic fibrosis, aspirin exacerbated respiratory disease, immunodeficiencies, allergic fungal rhinosinusitis and the relationship between upper and lower airways. The chapters on paediatric acute and chronic rhinosinusitis are totally rewritten. All available evidence for the management of acute rhinosinusitis and chronic rhinosinusitis with or without nasal polyps in adults and children is systematically reviewed and integrated care pathways based on the evidence are proposed. Despite considerable increases in the amount of quality publications in recent years, a large number of practical clinical questions remain. It was agreed that the best way to address these was to conduct a Delphi exercise . The results have been integrated into the respective sections. Last but not least, advice for patients and pharmacists and a new list of research needs are included. The full document can be downloaded for free on the website of this journal: http://www.rhinologyjournal.com.
Collapse
Affiliation(s)
- W J Fokkens
- Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands
| | - V J Lund
- Royal National Throat, Nose and Ear Hospital, UCLH, London, UK
| | - C Hopkins
- Ear, Nose and Throat Department, Guys and St. Thomas Hospital, London, United Kingdom
| | - P W Hellings
- Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands.,Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, KU Leuven, Belgium.,Upper Airways Research Laboratory and ENT Department, University Hospital Ghent, Ghent, Belgium
| | - R Kern
- Department of Otorhinolaryngology - Head and Neck Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
| | - S Reitsma
- Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands
| | - S Toppila-Salmi
- Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | | | | | - I Alobid
- Rhinology and Skull Base Unit, ENT Department, Hospital Clinic de Barcelona, Universidad de Barcelona, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
| | - W Terezinha Anselmo-Lima
- Division of Otorhinolaryngology, Department of Ophthalmology, Otorhinolaryngology, Head and Neck Surgery, Ribeirao Preto Medical School-University of Sao Paulo, Sao Paulo, Brazil
| | - C Bachert
- Upper Airways Research Laboratory and ENT Department, University Hospital Ghent, Ghent, Belgium.,Division of ENT Diseases, CLINTEC, Karolinska Institute, University of Stockholm, Stockholm, Sweden
| | - F Baroody
- Department of Otorhinolaryngology-Head and Neck Surgery, The University of Chicago Medicine and the Comer Children's Hospital, Chicago, IL, USA
| | - C von Buchwald
- Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University, Hospital, Copenhagen, Denmark
| | - A Cervin
- Department of Otorhinolaryngology, Head and Neck Surgery, Royal Brisbane and Women's Hospital.,Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - N Cohen
- Department of Otorhinolaryngology - Head and Neck Surgery, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA
| | - J Constantinidis
- 1st Department of ORL, Head and Neck Surgery, Aristotle University, AHEPA Hospital, Thessaloniki, Greece
| | - L De Gabory
- Rhinology and Plastic Surgery Unit, Otorhinolaryngology, Head and Neck Surgery and Pediatric ENT Department, CHU de Bordeaux, Hospital Pellegrin, Centre F-X Michelet, Bordeaux, France
| | - M Desrosiers
- Department of ORL-HNS, Universite de Montreal, Montreal, Canada
| | - Z Diamant
- Dept of Respiratory Medicine and Allergology, Skane University in Lund, Sweden.,Research Director Respiratory and Allergy, at QPS-Netherlands, Groningen, Netherlands.,Affiliate to Charles University, Dept of Respiratory Diseases, in Prague, Czech Republic
| | - R G Douglas
- Department of Surgery, The University of Auckland, Auckland, New Zealand
| | - P H Gevaert
- Department of Otorhinolaryngology, Ghent University, Ghent, Belgium
| | - A Hafner
- University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia
| | - R J Harvey
- Rhinology and Skull Base Department, Applied Medical Research Centre, UNSW (Conjoint) and Macquarie University (Clinical), Sydney, Australia
| | - G F Joos
- Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
| | - L Kalogjera
- ENT Department, Zagreb School of Medicine.,University Hospital Center "Sestre milosrdnice", Zagreb, Croatia
| | - A Knill
- Patient representative, Opuscomms, London, UK
| | - J H Kocks
- Department of Inhalation Medicine, Observational Pragmatic Research Institute, Singapore
| | - B N Landis
- Rhinology-Olfactology Unit, Otorhinolaryngology Department, University Hospital of Geneva, Geneva, Switzerland
| | - J Limpens
- Medical Information Specialist, Medical Library, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands
| | - S Lebeer
- Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium
| | - O Lourenco
- FCS - UBI Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal
| | - C Meco
- Department of Otorhinolaryngology, Head and Neck Surgery, Ankara University, Ankara, Turkey.,Department of Otorhinolaryngology, Head and Neck Surgery, Salzburg Paracelsus Medical University, Salzburg, Austria
| | - P M Matricardi
- Department of Pediatric Pneumology and Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany
| | - L O'Mahony
- Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland
| | - C M Philpott
- Department of Medicine, Norwich Medical School, University of East Anglia, Norwich, UK.,ENT Department, James Paget University Hospital, Great Yarmouth, UK
| | - D Ryan
- Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.,Optimum Patient Care, Cambridgeshire, UK
| | - R Schlosser
- Department of Otorhinolaryngology Head and Neck Surgery, Medical University of South Carolina, Charleston, USA
| | - B Senior
- UNC Otorhinolaryngology / Head and Neck Surgery, Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery and Department of Neurosurgery, University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - T L Smith
- Division of Rhinology and Sinus/Skull Base Surgery, Department of Otolaryngology-Head Neck Surgery, Oregon Health and Science University, Portland, OR, USA
| | - T Teeling
- Patient representative, Task Force Healthcare, WTC Den Haag, The Netherlands
| | - P V Tomazic
- Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Graz, Graz, Austria
| | - D Y Wang
- Department of Otorhinolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - D Wang
- Rhinology Division, ENT Department.,Eye and ENT Hospital, Fudan University, Shanghai, China
| | - L Zhang
- Department of Otorhinolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Beijing, China
| | - A M Agius
- Department of Medicine and Surgery in the University of Malta
| | | | - R Alabri
- ENT Division, Surgery Department, College of Medicine and Health and Sciences, Sultan Qaboos University, Muscat, Oman
| | - S Albu
- Department of Otorhinolaryngology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | | | - A Aleksic
- ENT Department, University Clinical Centre, University of Banja Luka, Bosnia and Herzegovina
| | - M Aloulah
- ENT Department, King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - M Al-Qudah
- Department of Otorhinolaryngology, Jordan University of Science and Technology, Irbid, Jordan
| | - S Alsaleh
- Department of Otorhinolaryngology - Head and Neck Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - M A Baban
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Sulaimani, Sulaimayniha, Iraq
| | - T Baudoin
- Dept. of ORL-HNS Sisters of Mercy University Medical Center, School of Medicine University of Zagreb, Croatia
| | - T Balvers
- Department of Neurology, Leiden University Medical Center (LUMC)
| | - P Battaglia
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - J D Bedoya
- Department of Otorhinolaryngology, Universidad de Antioquia, Medellin, Colombia
| | - A Beule
- Department of Otorhinolaryngology, University Clinic of Munster, Germany
| | - K M Bofares
- Department of Otorhinolaryngology, Omar Al-Moukhtar University, Albyeda, Libya
| | - I Braverman
- Department of Otorhinolaryngology - Head and Neck Surgery, Hillel Yaffe Medical Center, Israel
| | - E Brozek-Madry
- Department of Otorhinolaryngology, Medical University of Warsaw, Poland
| | - B Richard
- Department of ENT, Makerere University, Kampala, Uganda
| | - C Callejas
- Department of Otorhinolaryngology, Pontificia Catholic University, Santiago, Chile
| | - S Carrie
- Department of Otorhinolaryngology, Head and Neck Surgery, Newcastle University, United Kingdom
| | - L Caulley
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Ottawa,Toronto, Canada
| | - D Chussi
- Department of Otorhinolaryngology, Kilimanjaro Christian Medical University College, Moshi, Tanzania
| | - E de Corso
- Department of Otorhinolaryngology , La Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy
| | - A Coste
- ORL et Chirurgie Cervico-Faciale, Universite Paris-Est Creteil (UPEC), France
| | - U El Hadi
- Department of Otorhinolaryngology, American University of Beirut, Lebanon
| | - A Elfarouk
- Department of Otorhinolaryngology, Cairo University, Egypt
| | - P H Eloy
- Department of ENT, CHU UCL Namur, Yvoir, Belgium
| | - S Farrokhi
- Department of Immunology and Allergy, The Persian Gulf Tropical Medicine Research Center.,The Persian Gulf Biomedical Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
| | - G Felisati
- Department of Head and Neck, University of Milan, Italy
| | - M D Ferrari
- Department of Neurology, Leiden University Medical Center (LUMC)
| | - R Fishchuk
- Department of ENT- Organs Microsurgery, Central city clinical hospital of lvano-Frankivsk city council, Ivano-Frankivsk, Ukraine
| | - W Grayson
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Alabama Birmingham, USA
| | - P M Goncalves
- ENT Department, Centro Hospitalar de Entre Douro e Vouga, Santa Maria da Feira, Portugal
| | - B Grdinic
- ENT Department, General Hospital, Pula, Pula, Croatia
| | - V Grgic
- ENT Department, Zagreb School of Medicine.,University Hospital center 'Sestre milosrdnice', Zagreb, Croatia
| | - A W Hamizan
- Department of Otorhinolaryngology, University Kebangsaan, Kuala Lumpur, Malasyia
| | - J V Heinichen
- Department of ENT of Hospital de Clinicas, Facultad de Ciencias Medicas, Universidad Nacional de Asuncion, Paraguay
| | - S Husain
- Department of Otorhinolaryngology, Head and Neck Surgery, National University of Malaysia, Kuala Lumpur, Malaysia
| | - T I Ping
- Department ORLHNS, University Malaysia Sarawak, Kuching, Malaysia
| | - J Ivaska
- Clinic of Ear, Nose, Throat and Eye diseases, Vilnius University, Lithuania
| | - F Jakimovska
- ENT Department of Medical Faculty, St Cyril and Methodius University of Skopje, North Macedonia
| | - L Jovancevic
- Department of Otorhinolaryngology, Head and Neck Surgery, Clinical Centre of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia
| | - E Kakande
- Department of ENT Surgery, Mulago National Referral Hospital Kampala, Uganda
| | - R Kamel
- Department of Otorhinolaryngology, Head and Neck Surgery, Cairo University, Egypt
| | - S Karpischenko
- ENT Department, Director of Saint Petersburg Research Institute of Ear, Throat , Nose and Speech.,Professor and Chairman of First Pavlov State Medical University, Saint Petersburg, Russia
| | - H H Kariyawasam
- Department of Allergy and Clinical Immunology, Royal National ENT Hospital, London, England
| | - H Kawauchi
- 96. Department of Otorhinolaryngology, Shimane University, Matsue, Shimane, Japan
| | - A Kjeldsen
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Southern Denmark, Odense, Denmark
| | - L Klimek
- Center of Rhinology and Allergology, Wiesbaden, Hesse, Germany
| | - A Krzeski
- Department of Otorhinolaryngology, Warsaw Medical University, Warsaw, Poland
| | - G Kopacheva Barsova
- Department of Otorhinolaryngology, University If Medicine, st. Ciril and Methodius, Skopje
| | - S W Kim
- Department of Otorhinolaryngology, Head and Neck Surgery, Kyung Hee University, Seoul, South Korea
| | - D Lal
- Department of Otorhinolaryngology, Head and Neck Surgery, Mayo Clinic in Arizona, Phoenix, Arizona, USA
| | - J J Letort
- Department of Otorhinolaryngology, Pontifica Catholic University of Ecuador, Quito, Ecuador
| | - A Lopatin
- Department of Otorhinolaryngology, Policlinic No.1- Senior ENT Consultant and Surgeon.,President of Russian Rhinologic Society, Moscow, Russia
| | | | - A Mesbahi
- Department of Facial Surgery, Khodadoust Hospital, Ordibehesht Hospital, Shiraz, Iran
| | - J Netkovski
- Department of Otorhinolaryngology-Head and Neck Surgery, St. Cyril and Methodius, Skopje, Republic of North Macedonia
| | - D Nyenbue Tshipukane
- Department of Otorhinolaryngology, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - A Obando-Valverde
- Department of Otorhinolaryngology and Surgery, Hospital Mexico, University of Costa Rica, San Jose, Costa Rica
| | - M Okano
- Department of Otorhinolaryngology, International University of Health and Welfare, Narita , Japan
| | - M Onerci
- Department of Otorhinolaryngology, Hacettepe, Ankara, Turkey
| | - Y K Ong
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Singapore, National University Hospital, Singapore
| | - R Orlandi
- Department of Otorhinolaryngology, University of Utah, Salt Lake City, Utah, USA
| | - N Otori
- Department of Otorhinolaryngology at The Jikei University School of Medicine,Tokyo, Japan
| | - K Ouennoughy
- Department of Otorhinolaryngology-Head and Neck Surgery, Saad Dahleb Blida 1, Blida, Algeria
| | - M Ozkan
- Department of Otorhinolaryngology, University of Health Sciences, Ankara City Hospital, Turkey
| | - A Peric
- Department of Otorhinolaryngology, Military Medical Academy, Faculty of Medicine, University of Defense, Belgrade, Serbia
| | - J Plzak
- Department of Otorhinolaryngology, Head and Neck Surgery, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - E Prokopakis
- Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Crete, Greece
| | - N Prepageran
- Department of ENT, University Malaya, Kuala Lumpur, Malaysia
| | - A Psaltis
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Adelaide, Adelaide, Australia
| | - B Pugin
- Department of Health Sciences and Technology, ETH Zurich, Switzerland
| | - M Raftopulos
- Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands.,Royal Australian College of Surgeons, Trainee Representative (Australia)
| | - P Rombaux
- Department of Otorhinolaryngology, University of Louvain, Brussels, Belgium
| | - H Riechelmann
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Ulm, Baden-Wurttemberg, Germany
| | - S Sahtout
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia
| | - C-C Sarafoleanu
- ENT and H NS Department, Santa Maria Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - K Searyoh
- Surgery Ear, Nose and Throat Unit, School of Medicine and Dentistry, University of Ghana, Korle-Bu Teaching Hospital, Accra, Ghana
| | - C-S Rhee
- Department of Otorhinolaryngology, Head and Neck Surgery, Seoul, Seoul National University, Seoul, Korea
| | - J Shi
- Department of Rhinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - M Shkoukani
- Department of Otorhinolaryngology, Head and Neck Surgery, Cleveland Clinic Abu Dhabi, United Arab Emirates
| | - A K Shukuryan
- Department of Otorhinolaryngology, Yerevan State Medical University, Yerevan, Armenia
| | - M Sicak
- Department of Otorhinolaryngology, Head and Neck Surgery, Central Military Hospital, Slovakia, Slovak Health University Bratislava and Catholic University, Ruzom berok, Slovakia
| | - D Smyth
- Department of Otorhinolaryngology, Head and Neck Surgery, Royal College of Surgeons in Ireland and University College Cork, Waterford, Ireland
| | - K Sindvongs
- Department of Otorhinolaryngology, Chulalongkorn University, Bangkok, Thailand
| | - T Soklic Kosak
- University Medical Centre Ljubljana, Department of Otorhinolaryngology and Cervicofacial Surgery, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
| | - P Stjarne
- Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden
| | - B Sutikno
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Airlangga, Surabaya, Indonesia
| | - S Steinsvag
- Department of ORL, University of Bergen, Norway
| | - P Tantilipikorn
- Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - S Thanaviratananich
- Department of Otorhinolaryngology, Head and Neck Surgery, Cleveland Clinic Abu Dhabi, United Arab Emirates
| | - T Tran
- Department of ENT Hospital of Ho Chi Minh city, Faculty of medicine of Ho Chi Minh city Vietnam National University, Vietnam
| | - J Urbancic
- Department of Otorhinolaryngology and cervicofacial surgery, UMC Ljubljana, University of Ljubljana, Medical Faculty, Ljubljana, Slovenia
| | - A Valiulius
- Department of Children's diseases, Vilnius University Medical Faculty, Institute of Clinical Medicine, Vilnius, Lithuania
| | - C Vasquez de Aparicio
- Department of Paediatric Surgery, National Hospital Benjamin Bloom, National University of El Salvador, San Salvador, El Salvador
| | - D Vicheva
- Department of Otorhinolaryngology, Medical University Plovdiv, Bulgaria
| | - P M Virkkula
- Department of Otorhinolaryngology, Head and Neck Surgery, Helsinki, University Hospital, Helsinki, Finland
| | - G Vicente
- Department of Otolaryngology, St. Luke's Medical Centre, Quezon City, The Philippines
| | - R Voegels
- Department of Otorhinolaryngology, University of Sao Paulo, Sau Paulo, Brazil
| | - M M Wagenmann
- Department of Otorhinolaryngology, Dusseldorf University Hospital, Dusseldorf, German
| | - R S Wardani
- Department of Otorhinolaryngology Head and Neck Surgery, Dr. Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia
| | - A Welge-Lussen
- Department of Otorhinolaryngology, University Hospital Basel, University Basel, Switzerland
| | - I Witterick
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Ottawa,Toronto, Canada
| | - E Wright
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - D Zabolotniy
- State Institution of O.S. Kolomiychenko Institute of Othorhnilarungology of National Academy of Medical Sciences of Ukraine, Kiev, Ukraine
| | - B Zsolt
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Szeged, Hungary
| | - C P Zwetsloot
- Department of Neurology, Dijklander Ziekenhuis, Purmerend, The Netherlandsn
| |
Collapse
|
158
|
Zhao J, Shi J, Wu B, Bai X, Du H. Is the weight-reducing effect of aerobic exercise in mice mediated by a regulatory effect of SFRS10 on alternative splicing of PKCδI pre-mRNA? Sci Sports 2020. [DOI: 10.1016/j.scispo.2019.03.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
159
|
Kang Y, Yao JJ, Zhang ZH, Wang ZY, Wu H, Shi J. [The value of laryngoscopy and MRI in diagnosis and management of pharyngolaryngeal venous malformations]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2020; 33:1040-1043. [PMID: 31914290 DOI: 10.13201/j.issn.1001-1781.2019.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Indexed: 11/12/2022]
Abstract
Objective:To investigate the value of laryngoscopy and MRI in diagnosis and management of pharyngolaryngeal venous malformations(VMs), and to provide reliable evidences for clinical application. Method:The clinical data of 73 patients with pharyngolaryngeal VMs was analyzed retrospectively. Laryngoscopy and MRI were detected before treatment. The involved anatomic sites and the volume of VMs were calculated by Mimics version 20.0. Result:No significant difference was found in the detection rate of VMs between laryngoscopy and MRI(P>0.05). The most common sites involved in pharyngolaryngeal VMs were the tongue base(37.0%), followed by epiglottis(35.6%) and pyriform sinus(32.9%). The volume of pharyngolaryngeal VMs ranged from 0.75 cm³to 76.33 cm³, with an average volume of (17.43±6.28) cm³. Conclusion:Laryngoscopy and MRI have their own advantages in diagnosing of pharyngolaryngeal VMs. Thus a combination which provides more information to formulate reasonable treatment plan has great diagnosing value. When treating with facial and cervical VMs, routine laryngoscopy is recommended to screen and to evaluate the laryngopharyngeal involvement.
Collapse
Affiliation(s)
- Y Kang
- Department of Otolaryngology Head and Neck Surgery,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Ear Institute,Shanghai Key Laboratory of Translational Medicine on Ear and Nose diseases,Shanghai Jiao Tong University School of Medicine,Shanghai,200092,China
| | - J J Yao
- Department of Otolaryngology Head and Neck Surgery,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Ear Institute,Shanghai Key Laboratory of Translational Medicine on Ear and Nose diseases,Shanghai Jiao Tong University School of Medicine,Shanghai,200092,China
| | - Z H Zhang
- Department of Otolaryngology Head and Neck Surgery,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Ear Institute,Shanghai Key Laboratory of Translational Medicine on Ear and Nose diseases,Shanghai Jiao Tong University School of Medicine,Shanghai,200092,China
| | - Z Y Wang
- Department of Otolaryngology Head and Neck Surgery,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Ear Institute,Shanghai Key Laboratory of Translational Medicine on Ear and Nose diseases,Shanghai Jiao Tong University School of Medicine,Shanghai,200092,China
| | - H Wu
- Department of Otolaryngology Head and Neck Surgery,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Ear Institute,Shanghai Key Laboratory of Translational Medicine on Ear and Nose diseases,Shanghai Jiao Tong University School of Medicine,Shanghai,200092,China
| | - J Shi
- Department of Otolaryngology Head and Neck Surgery,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Ear Institute,Shanghai Key Laboratory of Translational Medicine on Ear and Nose diseases,Shanghai Jiao Tong University School of Medicine,Shanghai,200092,China
| |
Collapse
|
160
|
He J, Zhou WJ, Shi J, Lin JL, Zhang BQ, Sun ZH. [Analysis of genotypes, EEG and phenotypes of tuberous sclerosis complex patients]. Zhonghua Yi Xue Za Zhi 2020; 100:136-140. [PMID: 31937054 DOI: 10.3760/cma.j.issn.0376-2491.2020.02.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: Tuberous sclerosis complex (TSC) is a multi-system disease with TSC1 and TSC2 genes as the pathogenic genes. The purpose of our study was to analyze the gene mutation in patients with TSC with epilepsy as the main clinical manifestation. The relationship between genotype and phenotype, scalp EEG in patients was analyzed. Methods: The peripheral blood was extracted from 43 patients and their families. TSC gene was detected by second-generation sequencing. Long-term video EEG monitoring and MRI examination were performed to determine the onset area, seizure type and location of nodules. Results: 39 patients had TSC gene mutation, 4 patients did not detect the gene mutation.11 had TSC1 mutations and 28 had TSC2 mutations. 22 mutations were de novo. Patients with TSC2 mutations had earlier seizure and more nodules than patients with TSC1 mutations, but no significant difference in intelligence and spasm were observed. 28 patients had focal origin of scalp EEG, of which 85.7% of TSC2 mutations patients had focal origin. Conclusions: Patients of TSC2 mutations always has an early onset age. Although MRI shows multiple nodules, the onset of EEG is mainly focal origin.
Collapse
Affiliation(s)
- J He
- Department of Epilepsy Center, Tsinghua University Yuquan Hospital, Beijing 100049, China
| | | | | | | | | | | |
Collapse
|
161
|
Wen X, Shi J, Cui L, Wang YF, Huang AP, Liu YY, Song YL. [Analysis of related factors of secondary pulmonary infection in children with tracheobronchial foreign body]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2020; 33:1200-1202. [PMID: 31914274 DOI: 10.13201/j.issn.1001-1781.2019.12.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Indexed: 11/12/2022]
Abstract
Objective:To analyze the secondary pulmonary infection and the distribution of pathogenic bacteria in children with tracheobronchial foreign body, and to guide the clinical treatment. Method:The clinical data of 197 children with tracheobronchial foreign bodies confirmed by rigid bronchoscopy were reviewed. According to the clinical manifestations and signs, blood routine, chest CT and airway endocrine pathogen distribution, the secondary pulmonary infection was analyzed. Result:Seventy-five of 197 children with foreign bodies in tracheobronchial had secondary pulmonary infections. Among them, 32 cases of airway endocrine cultured pathogenic bacteria, mainly including Streptococcus pneumoniae and Haemophilus influenzae. Children with long preoperative history, fever, and with a history of using antibiotics are more likely to have secondary pulmonary infections. Conclusion:The duration of disease history, preoperative fever and the use of antibiotics are related to secondary pulmonary infection. The third generation of cephalosporins can effectively control the infection.
Collapse
Affiliation(s)
- X Wen
- Department of Otolaryngology,Hebei Children' s Hospital Affiliated to Hebei Medical University,Shijiazhuang,050031,China
| | - J Shi
- Department of Anesthesiology,Hebei Children' s Hospital Affiliated to Hebei Medical University
| | - L Cui
- Department of Otolaryngology,Hebei Children' s Hospital Affiliated to Hebei Medical University,Shijiazhuang,050031,China
| | - Y F Wang
- Department of Otolaryngology,Hebei Children' s Hospital Affiliated to Hebei Medical University,Shijiazhuang,050031,China
| | - A P Huang
- Department of Otolaryngology,Hebei Children' s Hospital Affiliated to Hebei Medical University,Shijiazhuang,050031,China
| | - Y Y Liu
- Department of Otolaryngology,Hebei Children' s Hospital Affiliated to Hebei Medical University,Shijiazhuang,050031,China
| | - Y L Song
- Department of Otolaryngology,Hebei Children' s Hospital Affiliated to Hebei Medical University,Shijiazhuang,050031,China
| |
Collapse
|
162
|
Shi J, Li X, Hu Y, Zhang F, Lv X, Zhang X, Chen Q, Hu S. MiR-1203 is involved in hepatocellular carcinoma metastases and indicates a poor prognosis. Neoplasma 2019; 67:267-276. [PMID: 31847527 DOI: 10.4149/neo_2019_190414n328] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2019] [Accepted: 06/26/2019] [Indexed: 11/08/2022]
Abstract
Non-coding RNAs, especially miRNAs, have been shown to be important regulators in multiple human diseases, including malignant tumors, congenital disease, and autoimmune disease. In this study, we screened the metastasis-associated miRNAs in hepatocellular carcinoma (HCC). Based on the miRNA microarray screening, miR-1203 was confirmed to be the most significant miRNA and was also highly associated with HCC metastases. Bioinformatics prediction indicated direct binding of miR-1203 in SOCS3, which was also confirmed by a dual luciferase reporter assay, resulting in suppression of SOCS3. Increased miR-1203 also promoted invasion of HCC cells through suppressing SOCS3, while no effect on cell proliferation or apoptosis was detected. Circulating expression of miR-1203 and SOCS3 might serve as a predictor of metastases and poor prognosis in HCC patients. In conclusion, miR-1203 might promote HCC metastasis by decreasing SOCS3. MiR-1203 predicts a poor outcome in HCC patients and thus might serve as a potential therapeutic target for the prevention of HCC.
Collapse
Affiliation(s)
- J Shi
- Department of General Surgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China.,Department of Hepatobiliary Surgery, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou, China
| | - X Li
- Department of Pediatrics, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou, China
| | - Y Hu
- Department of Hepatobiliary and Pancreatic Surgery, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Nanjing Medical University, Changzhou, China
| | - F Zhang
- Department of Hepatobiliary Surgery, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou, China
| | - X Lv
- Department of Hepatobiliary Surgery, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou, China
| | - X Zhang
- Department of Hepatobiliary Surgery, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou, China
| | - Q Chen
- Department of Hepatobiliary Surgery, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou, China
| | - S Hu
- Department of General Surgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
| |
Collapse
|
163
|
Shi J, Zhu ZM, Sun K, Lei PC, Liu ZW, Guo JM, Yang J, Zang YZ, Zhang Y. [Expression of CD45 in newly diagnosed multiple myeloma and the relationship with prognosis]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:744-749. [PMID: 31648475 PMCID: PMC7342442 DOI: 10.3760/cma.j.issn.0253-2727.2019.09.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
目的 观察CD45在初诊多发性骨髓瘤(MM)患者中的表达,探讨其与MM疗效和预后的关系。 方法 回顾性分析2010年1月至2017年1月河南省人民医院收治的130例初诊MM患者骨髓异常浆细胞中CD45的表达情况,对CD45+与CD45−患者的疗效和预后进行比较。 结果 ①130例初诊MM患者中CD45+组33例(25.38%),CD45−组97例(74.62%)。②CD45+组和CD45−组的客观缓解率(ORR)分别为33.33%和64.95%,差异有统计学意义(P=0.002);以硼替佐米为基础方案治疗的患者,CD45+组和CD45−组的ORR分别为35.71%和66.25%,差异有统计学意义(P=0.005)。③130例MM患者的中位无进展生存(PFS)时间为33.3(95%CI 6.0~69.0)个月,中位总生存(OS)时间为36.3(95%CI 6.0~78.0)个月,CD45+组与CD45−组的中位PFS时间分别为29.8(95%CI 10.0~59.0)个月和34.5(95%CI 6.0~69.0)个月,差异有统计学意义(χ2=14.59,P<0.001),中位OS时间分别为32.5(95%CI 10.0~68.0)个月和37.6(95%CI 6.0~78.0)个月,差异有统计学意义(χ2=11.42,P=0.001);接受硼替佐米的患者中,CD45+组与CD45−组的中位PFS分别为30.3(95%CI 10.0~59.0)个月和36.3(95%CI 6.0~69.0)个月,差异有统计学意义(χ2=14.75,P=0.001)。中位OS时间分别为34.0(95%CI 10.0~68.0)个月和39.5(95%CI 6.0~78.0)个月,差异有统计学意义(χ2=10.62,P=0.001)。④Cox风险回归模型分析显示血肌酐≥176.8 µmol/L[HR=2.723(95%CI 1.744~6.723),P=0.001]、CD45阳性[HR=1.330(95%CI 1.067~1.804),P=0.008],LDH ≥ 220 IU/L[HR=1.308(95%CI 1.160~2.417),P=0.015]是独立于其他临床指标的预后危险因素。 结论 CD45阳性是MM患者的预后不良因素。硼替佐米不能改善CD45+MM患者的不良预后。
Collapse
Affiliation(s)
- J Shi
- Henan Provincial People's Hospital, Zhengzhou 450003, China
| | | | | | | | | | | | | | | | | |
Collapse
|
164
|
Shi Y, Fang J, Shu Y, Wang D, Yu H, Zhao Y, Zhang L, Zhu B, Li X, Chen G, Shi J, Zheng R, Huang J, Yang S, Long J, Gao W, Greco M, Hu G, Li X. OA01.08 A Phase I Study to Evaluate Safety and Antitumor Activity of BPI-7711 in EGFRM+/T790M+ Advanced or Recurrent NSCLC Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
165
|
Shi Y, Fang J, Shu Y, Wang D, Yu H, Zhao Y, Zhang L, Zhu B, Li X, Chen G, Shi J, Zheng R, Huang J, Yang S, Long J, Gao W, Greco M, Hu G, Li X. A phase I study to evaluate safety and efficacy of BPI-7711 in EGFRm+/T790M+ advanced or recurrent NSCLC patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
166
|
Shi J, Sun K, Zhu ZM, Lei PC, Liu ZW, Chen YQ, Guo JM, Zang YZ, Yang J, Zhang Y. [Prognostic significance of CD56 and CD117 expression in patients with newly diagnosed multiple myeloma treated with bortezomib-based first-line therapy]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:693-696. [PMID: 31495142 PMCID: PMC7342872 DOI: 10.3760/cma.j.issn.0253-2727.2019.08.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J Shi
- Department of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
167
|
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Zhou Y, Tai Y. OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.425] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
168
|
Han B, Li K, Chu T, Bi M, Zhang H, Yu Y, Shi J, Zhang X, Chen Z, Han C, Bai T. P1.01-03 Efficacy and Safety of Biosimilar QL1101 Compared with Avastin in Patients with Non-Squamous Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
169
|
Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Lou D, Yu H, Qin H, Li XL. Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz264.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
170
|
Li K, Cheng Y, Wang Q, Shi J, Han B, Wu L, Chen G, He J, Wang J, Qin H, Li X. P2.12-11 Quality of Life in ALTER1202 Trial of Anlotinib as Third-or Further Line Therapy for Advanced Small Cell Lung Cancer (SCLC): A Post-Hoc Analysis. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
171
|
Wang Q, Cheng Y, Li K, Shi J, Han B, Wu L, Chen G, He J, Wang J, Qin H, Li X. OA03.02 Effect of Anlotinib in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
172
|
Elkoustaf R, Patel M, Rao R, Batiste C, Quon S, Newman D, Shi J. P5497The gender paradox in non-ST-segment elevation acute coronary syndrome: an outdated paradigm or a persistent reality-an analysis of contemporary practice from an integrate health care system. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Although sex related differences in Non-ST-Segment elevation (NSTEMI) acute coronary syndrome (ACS) have been well delineated in the past, there is a paucity of data from contemporary practice on the evolutions of this paradox and its clinical practice implications.
Purpose
We hypothesized that in the era of guideline driven contemporary practice, and in the setting of an integrated heath care model, gender related differences in care and outcomes would be marginal at best if no altogether absent.
Methods
We utilized data from an integrated health care system to identify 4099 patients with NSTEMI-ACS (1531 women; 2561 men). The patients were stratified by gender and a comparative analysis was performed on guideline directed medical therapy, revascularization strategy and major adverse cardiac events between the two groups.
Results
There were significant difference in pharmacologic treatment, catheter based interventions and surgical revascularizations strategies. Underutilization of guideline directed medical therapy was demonstrated in women specifically vis a vis angiotensin converting enzyme inhibitor (ACE-I) (p=0.0014), statins (p=0.0001), and antiplatelet therapy: clopodigrel (p=0.0004), prasugrel (p=0.0012), and ticagrelor (p=0.03). Additionally, clear differences emerged in percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) options despite similarities in high risk status at index presentation by well validated risk algorithms. Specifically, men were more likely to undergo PCI (p=0.021) and CABG (p<0.001) than women. Finally, women had a greater incidence of bleeding complications (p=0.0003) and stroke (p=0,038).
Conclusions
There were treatment disparities in pharmacologic interventions, catheter based interventions, surgical revascularization access and clinical outcomes among patients with NSTEMI-ACS. The persistence of this gender paradox in contemporary practice and despite increasing education and awareness should potentiate further public policy initiatves as well as reinforce the need for geneder specific guidelines
Collapse
Affiliation(s)
- R Elkoustaf
- Southern California Permanente Medical Group, Riverside, United States of America
| | - M Patel
- Southern California Permanente Medical Group, Riverside, United States of America
| | - R Rao
- Southern California Permanente Medical Group, Riverside, United States of America
| | - C Batiste
- Southern California Permanente Medical Group, Riverside, United States of America
| | - S Quon
- Southern California Permanente Medical Group, Riverside, United States of America
| | - D Newman
- Southern California Permanente Medical Group, Riverside, United States of America
| | - J Shi
- Southern California Permanente Medical Group, Riverside, United States of America
| |
Collapse
|
173
|
Cao J, Guo W, Niu Z, Wang Z, Hu W, Ma X, Liu D, Shi J, Yao M. Genomic profiling in Chinese biliary tract cancer patients with PI3K/AKT/mTOR pathway and RAS gene mutations. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
174
|
Shi J, Xing YM, Qian J, Yang H, Luo L, Kong DH, Pan CZ, Shu XH, Ge J. P4348Early assessment of left ventricular function by layer-specific strain and its relationship to pulsatile arterial load in patients with coronary slow flow. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Previous studies reported controversial Left ventricular (LV) function impairment and pathophysiology in patients with coronary slow flow (CSF). Greater arterial load has been shown to increase aortic impedance and endothelial shear stress, potentially affecting coronary anatomy and function. We investigated LV systolic function by a new layer-specific strain technology and assessed the association between pulsatile arterial load and contractility.
Methods and results
A total of 70 patients with CSF and 50 controls with normal coronary angiography were included in the study. Layer-specific longitudinal and circumferential strains were assessed from endocardium, mid-myocardium and epicardium (GLS-endo, GLS-mid, GLS-epi and GCS-endo, GCS-mid, GCS-epi) by two-dimensional speckle tracking imaging (2D-STI). Pulsatile arterial load was estimated by indexed arterial compliance (ACI). Layer-specific GLS showed a decreasing gradient from the endocardium to the epicardium in both controls and CSF group. GLS-endo and GLS-mid in CSF group were significantly lower than the control group (all P<0.05). Layer-specific longitudinal strain showed a good correlation with the number of affected coronary arteries (all P<0.05) and the mean thrombolysis in myocardial infarction frame count (TFC) (all P<0.05). ACI was lower in CSF patients (P=0.005) and ACI was correlated negatively with layer-specific GLS (all P<0.05).
Conclusion
Layer-specific evaluation of the LV provides an understanding of the layer-specific properties of the LV wall and the possible process of the LV impairment in patients with CSF. Greater pulsatile arterial load, as manifested by a lower ACI, is coupled with worse LV longitudinal function in CSF patients.
Collapse
Affiliation(s)
- J Shi
- Zhongshan Hospital, Fudan University, Department of Echocardiography, Shanghai, China
| | - Y M Xing
- Zhongshan Hospital, Fudan University, Department of Echocardiography, Shanghai, China
| | - J Qian
- Zhongshan Hospital, Fudan University, Department of Echocardiography, Shanghai, China
| | - H Yang
- Zhongshan Hospital, Fudan University, Department of Echocardiography, Shanghai, China
| | - L Luo
- Zhongshan Hospital, Fudan University, Department of Echocardiography, Shanghai, China
| | - D H Kong
- Zhongshan Hospital, Fudan University, Department of Echocardiography, Shanghai, China
| | - C Z Pan
- Zhongshan Hospital, Fudan University, Department of Echocardiography, Shanghai, China
| | - X H Shu
- Zhongshan Hospital of Fudan University, Shanghai, China
| | - J Ge
- Zhongshan Hospital, Fudan University, Department of Echocardiography, Shanghai, China
| |
Collapse
|
175
|
Shi YK, Jiang S, Qin Y, Jiang H, Liu B, Shi J, Meng F, Liu P, Yang J, Yang S, He X, Zhou S, Gui L, Liu H, Lin J. Molecular profiling and prognostic significance of TP53 mutations in diffuse large b cell lymphoma: Identifying a high-risk subgroup. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
176
|
Cheng Y, Wang Q, Li K, Shi J, Han B, Wu L, Chen G, He J, Wang J, Qin H, Li X. P2.12-26 The Impact of Anlotinib for Relapsed SCLC Patients with Brain Metastases: A Subgroup Analysis of ALTER 1202. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1771] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
177
|
Lu S, Chen G, Sun Y, Sun S, Chang J, Yao Y, Chen Z, Ye F, Lu J, Shi J, He J, Liu X, Zhang Y, Liu Z, Fang J, Cheng Y, Hu C, Mao W, Hu Y, Gong Y, Shan L, Yang Z, Song Y, Li W, Bai C, Wang B, Ma R, Zheng Z, Liu M, Jie Z, Cao L, Liao W, Pan H, Huang D, Chen Y, Yang J, Qin S, Ma S, Liang L, Liu Z, Zhou J, Tao M, Huang Y, Qiu F, Huang Y, Hua Y, Chen Y, Su W. MA14.05 A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.613] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
178
|
Shi J, Wang YS, Zhao WP, Pan CZ, Shu XH. P4376Circumferential ascending aortic strain in healthy adults aged 24 to 75 years. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Two-dimensional speckle-tracking echocardiography (2D-STE) for the measurement of circumferential ascending thoracic aortic strain (CAAS) in healthy adults is not elucidated. We aimed to establish normal adult STE-derived CAAS and to evaluate associations with age, gender and other physiologic parameters.
Methods
One hundred eighty-one healthy subjects aged 24–75 were prospectively gathered and examined with two-dimensional echocardiography. The global peak CAAS was the parameter used, and an average of six segments of arterial wall deformation was calculated. The corrected CAAS was calculated as the global CAAS/pulse pressure (PP). Aortic stiffness (β2) index was assessed according to ln(Ps/Pd)/CAAS.
Results
We included 171 healthy subjects (age 44.3±10.9 years, 50% female, CAAS16.0±6.9%). The CAAS was independently predicted by age (β=−0.387, P<0.001), and gender (β=−2.701, P=0.001). The corrected CAAS was independently predicted by age (β=−0.009, P<0.001), SAC (β=−0.206, P<0.001) and gender (β=−0.068, P=0.001). The β2 index was independently predicted by age (β=0.136, P<0.001), and PP (β=0.059, P=0.007).
Conclusion
CAAS using 2D-STE can be performed on a clinical basis and may become an important method for the assessment of aortic mechanical parameter. Age, gender and LV afterload-related variables were the most import determinants of 2D-STE global CAAS. Therefore, these factors should be taken into account for strain interpretation in clinical practice.
Collapse
Affiliation(s)
- J Shi
- Zhongshan Hospital of Fudan University, Shanghai, China
| | - Y S Wang
- Zhongshan Hospital of Fudan University, Shanghai, China
| | - W P Zhao
- Zhongshan Hospital of Fudan University, Shanghai, China
| | - C Z Pan
- Zhongshan Hospital of Fudan University, Shanghai, China
| | - X H Shu
- Zhongshan Hospital of Fudan University, Shanghai, China
| |
Collapse
|
179
|
Liu Y, Yuan HL, Duan XL, Xu JL, Qu JH, Chen G, Shi J, Han CX, Ding LL, Jiang M. [Clinical research of HLA-haploidentical peripheral hematopoietic stem cell transplantation following reduced intensity conditioning regimen with hematological malignancy patients over 50 years old]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:667-672. [PMID: 31495134 PMCID: PMC7342871 DOI: 10.3760/cma.j.issn.0253-2727.2019.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
目的 分析减低剂量预处理单倍型外周血造血干细胞移植(RIC-haplo-PBSCT)治疗50岁以上恶性血液肿瘤患者的疗效。 方法 18例50岁以上恶性血液肿瘤患者纳入研究,男8例,女10例,中位年龄52(50~66)岁;急性髓系白血病(AML)8例,慢性髓性白血病(CML)2例,骨髓增生异常综合征(MDS)5例,急性淋巴细胞白血病(ALL)2例,急性NK细胞白血病(ANKL)1例;采用FAB+ATG(氟达拉滨+阿糖胞苷+白消安+兔抗人胸腺细胞免疫球蛋白)减低剂量预处理方案,输注供者高剂量非去T细胞外周血造血干细胞(PBSC),应用强化移植物抗宿主病(GVHD)预防方案及感染防控措施。 结果 16例患者在移植后15 d获得完全供者嵌合,其中1例在移植后1个月发生移植排斥,其余2例在移植后15 d为混合嵌合并于移植后1个月发生移植排斥。急性GVHD发生率为61.1%(95%CI 49.6%~72.6%),Ⅱ~Ⅳ度急性GVHD发生率为35.4%(95%CI 21.1%~49.7%),Ⅲ/Ⅳ度急性GVHD发生率为13.8%(95%CI 4.7%~22.9%)。2年慢性GVHD累积发生率为38.2%(95%CI 25.5%~50.9%),未发生广泛型慢性GVHD。中位随访14.5(3~44)个月,2年总生存率、无病生存率分别为72.6%(95%CI 60.1%~85.1%)、63.7%(95%CI 49.2%~78.2%),2年累积复发率为31.2%(95%CI 16.5%~45.9%),2年非复发死亡率为12.5%(95%CI 4.2%~20.8%)。 结论 RIC-haplo-PBSCT治疗50岁以上恶性血液肿瘤患者可获得较好的疗效。
Collapse
Affiliation(s)
- Y Liu
- Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China; Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi 830061, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
180
|
Shi J, Zhao W, Ying H, Du J, Chen J, Chen S, Shen B. The relationship of platelet to lymphocyte ratio and neutrophil to monocyte ratio to radiographic grades of knee osteoarthritis. Z Rheumatol 2019; 77:533-537. [PMID: 28681116 DOI: 10.1007/s00393-017-0348-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
OBJECTIVE Accumulating data show that platelet to lymphocyte ratio (PLR) and neutrophil to monocyte ratio (NMR) undergo changes during inflammation in various diseases; however, the clinical features remain unclear in knee osteoarthritis (OA) patients. The purpose of our study was to evaluate PLR and NMR in knee OA patients, and assess their relationship to knee OA's radiographic grades. METHODS A retrospective study on 132 adult knee OA patients and 162 healthy controls (HC) was performed. All clinical characteristics of the knee OA patients were obtained from their medical records. PLR and NMR were compared between knee OA patients and HC by non-parametric tests. Correlations of PLR and NMR with Kellgren-Lawrence (KL) classification (KL grade 2, KL grade 3, and KL grade 4) were also analyzed through a Spearman correlation test. Ordinal polytomous logistic regression was used to determine independent factors influencing radiographic grades of knee OA patients. RESULTS PLR was increased significantly in knee OA patients, while a statistical difference in NMR was not observed. However, PLR was not relevant to KL grades, while NMR was negatively correlated with these (r = -0.330, P < 0.01) and was independently associated with KL grades of knee OA. CONCLUSION PLR could reflect the inflammation response of knee OA. NMR emerged as an independent factor and could be used as a potential marker indicating the severity of knee OA.
Collapse
Affiliation(s)
- J Shi
- Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang Province, China
| | - W Zhao
- Wenzhou Medical University, Wenzhou, Zhejiang Province, China
| | - H Ying
- Wenzhou Medical University, Wenzhou, Zhejiang Province, China
| | - J Du
- Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang Province, China
| | - J Chen
- Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang Province, China
| | - S Chen
- Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang Province, China
| | - B Shen
- Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang Province, China.
| |
Collapse
|
181
|
Morley LC, Shi J, Gaunt HJ, Hyman AJ, Webster PJ, Williams C, Forbes K, Walker JJ, Simpson NAB, Beech DJ. Piezo1 channels are mechanosensors in human fetoplacental endothelial cells. Mol Hum Reprod 2019; 24:510-520. [PMID: 30085186 PMCID: PMC6311101 DOI: 10.1093/molehr/gay033] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Accepted: 08/02/2018] [Indexed: 01/10/2023] Open
Abstract
STUDY QUESTION Does the shear stress sensing ion channel subunit Piezo1 have an important mechanotransduction role in human fetoplacental endothelium? SUMMARY ANSWER Piezo1 is present and functionally active in human fetoplacental endothelial cells, and disruption of Piezo1 prevents the normal response to shear stress. WHAT IS KNOWN ALREADY Shear stress is an important stimulus for maturation and function of placental vasculature but the molecular mechanisms by which the force is detected and transduced are unclear. Piezo1 channels are Ca2+-permeable non-selective cationic channels which are critical for shear stress sensing and maturation of murine embryonic vasculature. STUDY DESIGN, SAMPLES/MATERIALS, METHODS We investigated the relevance of Piezo1 to placental vasculature by studying human fetoplacental endothelial cells (FpECs) from healthy pregnancies. Endothelial cells were isolated from placental cotyledons and cultured, for the study of tube formation and cell alignment to shear stress. In addition, human placental arterial endothelial cells were isolated and studied immediately by patch-clamp electrophysiology. MAIN RESULTS AND THE ROLE OF CHANCE The synthetic Piezo1 channel agonist Yoda1 caused strong elevation of the intracellular Ca2+ concentration with a 50% effect occurring at about 5.4 μM. Knockdown of Piezo1 by RNA interference suppressed the Yoda1 response, consistent with it being mediated by Piezo1 channels. Alignment of cells to the direction of shear stress was also suppressed by Piezo1 knockdown without loss of cell viability. Patch-clamp recordings from freshly isolated endothelium showed shear stress-activated single channels which were characteristic of Piezo1. LIMITATIONS, REASONS FOR CAUTION The in vitro nature of fetoplacental endothelial cell isolation and subsequent culture may affect FpEC characteristics and PIEZO1 expression. In addition to Piezo1, alternative shear stress sensing mechanisms have been suggested in other systems and might also contribute in the placenta. WIDER IMPLICATIONS OF THE FINDINGS These data suggest that Piezo1 is an important molecular determinant of blood flow sensitivity in the placenta. Establishing and manipulating the molecular mechanisms regulating shear stress sensing could lead to novel therapeutic strategies to improve blood flow in the placenta. LARGE-SCALE DATA Not applicable. STUDY FUNDING/COMPETING INTEREST(S) LCM was funded by a Clinical Research Training Fellowship from the Medical Research Council and by the Royal College of Obstetricians and Gynaecologists, and has received support from a Wellcome Trust Institutional Strategic Support Fund. JS was supported by the Wellcome Trust and a BHF Intermediate Research Fellowship. HJG, CW, AJH and PJW were supported by PhD Studentships from BHF, BBSRC and the Leeds Teaching Hospitals Charitable Foundation respectively. All authors declare no conflict of interest.
Collapse
Affiliation(s)
- L C Morley
- Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, UK
| | - J Shi
- Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, UK
| | - H J Gaunt
- Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, UK
| | - A J Hyman
- Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, UK
| | - P J Webster
- Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, UK
| | - C Williams
- Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, UK
| | - K Forbes
- Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, UK
| | - J J Walker
- Academic Department of Obstetrics and Gynaecology, Level 9 Worsley Building, School of Medicine, University of Leeds, Leeds, UK
| | - N A B Simpson
- Academic Department of Obstetrics and Gynaecology, Level 9 Worsley Building, School of Medicine, University of Leeds, Leeds, UK
| | - D J Beech
- Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, UK
| |
Collapse
|
182
|
Li Q, Li H, Shi J, He B, Yu F. Complement alternative pathway activation associated with pulmonary hypertension in lupus nephritis patients. Lupus 2019; 28:1051-1061. [PMID: 31296141 DOI: 10.1177/0961203319860192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Pulmonary hypertension occurs in systemic lupus erythematosus (SLE) for several reasons, such as vasculopathy. Previous studies have indicated that the excessive activation of the complement alternative pathway might be involved in the pathogenesis of lupus nephritis, especially in the absence of factor H or its functional impairment. However, the clinical and pathological significance of the alternative complement activation in lupus nephritis patients with pulmonary hypertension remains elusive. The data on patients with pulmonary hypertension and non-pulmonary hypertension lupus nephritis were retrospectively analyzed in our centre. Major plasma levels of complement components were evaluated. The depositions of Bb, C3d and C5b-9 in the lung specimens of pulmonary hypertension combined with SLE patients were detected by immunofluorescence staining. Among 352 lupus nephritis cases, 24 were diagnosed with pulmonary hypertension and 328 with non-pulmonary hypertension. Higher levels of Bb and lower levels of factor H were detected in the pulmonary hypertension group in comparison with the negative group (P = 0.049, P = 0.024, respectively). Pulmonary hypertension was a risk factor for renal outcome as deduced by the log-rank and Cox test for survival analysis. C3d, C5b-9 and Bb were found to be positive in lung specimens of lupus nephritis patients with pulmonary hypertension. We concluded that activation of the complement alternative pathway may be involved in the pathogenesis of pulmonary hypertension in lupus nephritis.
Collapse
Affiliation(s)
- Q Li
- 1 Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China
| | - H Li
- 2 MOE Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Xi'an, China
| | - J Shi
- 2 MOE Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Xi'an, China
| | - B He
- 1 Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China
| | - F Yu
- 3 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China.,4 Department of Nephrology, Peking University International Hospital, Beijing, China
| |
Collapse
|
183
|
Ravi V, Catha M, D'Addario L, Djorgovski SG, Hallinan G, Hobbs R, Kocz J, Kulkarni SR, Shi J, Vedantham HK, Weinreb S, Woody DP. A fast radio burst localized to a massive galaxy. Nature 2019; 572:352-354. [PMID: 31266051 DOI: 10.1038/s41586-019-1389-7] [Citation(s) in RCA: 195] [Impact Index Per Article: 39.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Accepted: 06/25/2019] [Indexed: 11/09/2022]
Abstract
Intense, millisecond-duration bursts of radio waves (named fast radio bursts) have been detected from beyond the Milky Way1. Their dispersion measures-which are greater than would be expected if they had propagated only through the interstellar medium of the Milky Way-indicate extragalactic origins and imply contributions from the intergalactic medium and perhaps from other galaxies2. Although several theories exist regarding the sources of these fast radio bursts, their intensities, durations and temporal structures suggest coherent emission from highly magnetized plasma3,4. Two of these bursts have been observed to repeat5,6, and one repeater (FRB 121102) has been localized to the largest star-forming region of a dwarf galaxy at a cosmological redshift of 0.19 (refs. 7-9). However, the host galaxies and distances of the hitherto non-repeating fast radio bursts are yet to be identified. Unlike repeating sources, these events must be observed with an interferometer that has sufficient spatial resolution for arcsecond localization at the time of discovery. Here we report the localization of a fast radio burst (FRB 190523) to a few-arcsecond region containing a single massive galaxy at a redshift of 0.66. This galaxy is different from the host of FRB 121102, as it is a thousand times more massive, with a specific star-formation rate (the star-formation rate divided by the mass) a hundred times smaller.
Collapse
Affiliation(s)
- V Ravi
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA. .,Center for Astrophysics, Harvard and Smithsonian, Cambridge, MA, USA.
| | - M Catha
- Owens Valley Radio Observatory, California Institute of Technology, Big Pine, CA, USA
| | - L D'Addario
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - S G Djorgovski
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - G Hallinan
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - R Hobbs
- Owens Valley Radio Observatory, California Institute of Technology, Big Pine, CA, USA
| | - J Kocz
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - S R Kulkarni
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - J Shi
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - H K Vedantham
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA.,ASTRON, Netherlands Institute for Radio Astronomy, Dwingeloo, The Netherlands
| | - S Weinreb
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, Pasadena, CA, USA
| | - D P Woody
- Owens Valley Radio Observatory, California Institute of Technology, Big Pine, CA, USA
| |
Collapse
|
184
|
Abstract
Although Flotillin 1 (FLOT1) is highly expressed in various human cancers, its relationship with ovarian cancer (OC) remains unknown. This study determines FLOT1 expression in human ovarian tumors and examines its effect on OC cell proliferation. FLOT1 protein expression was assessed in a tissue microarray by immunohistochemical staining. We found that 81.48% malignant and 50% borderline tumors were FLOT1 protein-positive, whereas benign tumors and normal ovarian tissues were negative. The staining was strongest in serous malignant tumor and transitional cell carcinoma and weakest in mucinous tumor. Differentially expressed FLOT1 in freshly isolated serous tumors was confirmed by Western blot and we then evaluated FLOT1 expression association with OC patients' clinical characteristics. Histological typing established that FLOT1 protein expression was significantly associated with serous tumor (P Keywords: cell proliferation, epithelial ovarian cancer, FLOT1, miRNA, therapeutic target, tumorigenesis.
Collapse
Affiliation(s)
- J Li
- Department of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, China
| | - X Zuo
- Department of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, China
| | - J Shi
- Center Laboratory, Jinshan Hospital, Fudan University, Shanghai, China
| | - J Zhang
- Center Laboratory, Jinshan Hospital, Fudan University, Shanghai, China
| | - X Duan
- Department of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shanghai, China
| | - G Xu
- Center Laboratory, Jinshan Hospital, Fudan University, Shanghai, China,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| |
Collapse
|
185
|
Wu Z, Shi J, Song Y, Zhao J, Sun J, Chen X, Gao P, Wang Z. Claudin-7 (CLDN7) is overexpressed in gastric cancer and promotes gastric cancer cell proliferation, invasion and maintains mesenchymal state. Neoplasma 2019; 65:349-359. [PMID: 29788731 DOI: 10.4149/neo_2018_170320n200] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 07/12/2017] [Indexed: 11/08/2022]
Abstract
Gastric cancer (GC) ranks as the fourth most common cancer worldwide and is among the most aggressive types of cancer. Claudin-7 (CLDN7) has been found to be aberrantly expressed in some types of cancers. However, the expression and role of CLDN7 on gastric cancer (GC) remain largely unknown. In this study, we have performed the largest expression analysis study to date of CLDN7 in 113 pairs of human GC tissues and non-tumorous adjacent tissues. We found CLDN7 expression is significantly elevated in GC tissues, and the overexpression of CLDN7 is closely related to lymph node metastasis. Furthermore, we observed that CLDN7 executes an oncogenic function, promoting cancer cell proliferation, invasion, and epithelial-mesenchymal transition in GC. Given this oncogenic role of CLDN7 in GC formation and progression, CLDN7 may have an indispensable potential for future anti-metastatic and therapeutic applications.
Collapse
Affiliation(s)
- Z Wu
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, China Medical University, Shenyang, China
| | - J Shi
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, China Medical University, Shenyang, China
| | - Y Song
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, China Medical University, Shenyang, China
| | - J Zhao
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, China Medical University, Shenyang, China
| | - J Sun
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, China Medical University, Shenyang, China
| | - X Chen
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, China Medical University, Shenyang, China
| | - P Gao
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, China Medical University, Shenyang, China
| | - Z Wang
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, China Medical University, Shenyang, China
| |
Collapse
|
186
|
Wu X, Zhang W, Li H, You S, Shi J, Zhang C, Shi R, Huang Z, Cao Y, Zhang X. Plasma C-type lectin-like receptor 2 as a predictor of death and vascular events in patients with acute ischemic stroke. Eur J Neurol 2019; 26:1334-1340. [PMID: 31081579 DOI: 10.1111/ene.13984] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 05/06/2019] [Indexed: 01/07/2023]
Abstract
BACKGROUND AND PURPOSE C-type lectin-like receptor 2 (CLEC-2) has prominent involvement in platelet activation, which is increased in coronary heart disease and acute ischaemic stroke (AIS) and is associated with stroke progression and stroke prognosis. Here, the aim was to examine the prognostic value of CLEC-2 in death and vascular event recurrence in AIS patients. METHODS In all, 352 patients with AIS were studied prospectively. All patients were followed up for 1 year. Death for all vascular events and a combination of death and vascular diseases (recurrent stroke, myocardial infarction, hospitalized and treated angina, hospitalized and treated peripheral arterial disease) were recorded. RESULTS During 1 year of follow-up, 46 patients (14.2%) experienced death or combined end-points (23 death and 46 combined end-points). Plasma CLEC-2 (pCLEC-2) was significantly associated with an increased risk of death and combined events of death and vascular diseases after adjusting for age, sex, history of hypertension, diabetes mellitus and coronary artery disease, and National Institutes of Health Stroke Scale scores. Each 1 SD higher log-transformed pCLEC-2 was associated with a 4.27-fold (hazard ratio 4.27, 95% confidence interval 1.71-10.65) increased risk for death and a 2.42-fold increased risk for combined end-points (hazard ratio 2.42, 95% confidence interval 1.52-3.86). The optimal cut-off point of pCLEC-2 for predicting death was 184.38 pg/ml. CONCLUSIONS Higher pCLEC-2 levels at admission were associated with increased risk of death and combined events of death and vascular diseases in patients with AIS, which indicated that pCLEC-2 is an important prognostic factor for AIS.
Collapse
Affiliation(s)
- X Wu
- Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - W Zhang
- Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - H Li
- Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - S You
- Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - J Shi
- Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - C Zhang
- Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - R Shi
- Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Z Huang
- Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Y Cao
- Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - X Zhang
- Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| |
Collapse
|
187
|
Zhou LW, Shi J, Huang ZD, Nie N, Shao YQ, Li XX, Ge ML, Zhang J, Jin P, Huang JB, Zheng YZ. [Clonal evolution and clinical significance of trisomy 8 in acquired bone marrow failure]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:507-511. [PMID: 31340625 PMCID: PMC7342404 DOI: 10.3760/cma.j.issn.0253-2727.2019.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/23/2018] [Indexed: 11/25/2022]
Abstract
Objective: To analyze clonal evolution and clinical significance of trisomy 8 in patients with acquired bone marrow failure. Methods: The clinical data of 63 patients with acquired bone marrow failure accompanied with isolated trisomy 8 (+8) from June 2011 to September 2018 were analyzed retrospectively, the clonal evolution patterns and relationship with immmunosuppressive therapy were summarized. Results: Totally 24 male and 39 female patients were enrolled, including 39 patients with aplastic anemia (AA) and 24 patients with relatively low-risk myelodysplastic syndrome (MDS) . Mean size of+8 clone in MDS patients[65% (15%-100%) ]was higher than that of AA patients[25% (4.8%-100%) , z=3.48, P=0.001]. The patients were was divided into three groups (<30%, 30%-<50%,and ≥50%) according to the proportion of+8 clone. There was significant difference among the three groups between AA[<30%:55.6% (20/36) ; 30-50%: 22.2% (8/36) ; ≥50%22.2% (8/36) ]and MDS patients[<30%:19.0% (4/21) ; 30%-<50%:19.0% (4/21) ; ≥50%61.9% (13/21) ] (P=0.007) . The proportion of AA patients with+8 clone <30% was significantly higher than that of MDS patients (P=0.002) ; and the proportion of AA patients with+8 clone ≥50%was significantly lower than that of MDS patients (P=0.002) . The median age of AA and MDS patients was respectively 28 (7-61) years old and 48.5 (16-72) years old. Moreover, there was no correlation between age and+8 clone size in AA or MDS (r(s)=0.109, P=0.125; r(s)=-0.022, P=0.924, respectively) . There was statistical difference in total iron binding capacity, transferrin and erythropoietin between high and low clone group of AA patients (P=0.016, P=0.046, P=0.012, respectively) , but no significant difference in MDS patients. The immunosuppressive therapy (IST) efficacy of AA and MDS patients was respectively 66.7% and 43.8% (P=0.125) . Comparing with initial clone size (27.3%) , the +8 clone size (45%) of AA patients was increased 1-2 year after IST, but no statistical difference (z=0.83, P=0.272) . Consistently, there was no significant change between initial clone size (72.5%) and 1-2 year clone size (70.5%) after IST in MDS patients. There was no significant difference in IST efficient rate between +8 clone size expansion and decline group of in AA patients at 0.5-<1, 1-2 and>2 years after IST. We found four dynamic evolution patterns of +8 clone, which were clone persistence (45%) , clone disappearance (30%) , clone emergence (10%) and clone recurrence (15%) . Conclusions: AA patients had a low clone burden, while MDS patients had a high burden of +8 clone. The +8 clone of AA patients didn't significantly expanded after IST, and the changes of +8 clone also had no effect on IST response.
Collapse
Affiliation(s)
- L W Zhou
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China; State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
188
|
Shi J, Li X, Sun L, Lu Y. 811 Effect of low concentration of hydrogen peroxide treatment on cellular aging and autophagy in human melanocytes. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
189
|
Si J, Shen H, Shi J, Shen G. Will inferior alveolar nerve injury during bilateral sagittal split ramus osteotomy impair the bone healing of human mandible? Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
190
|
Liu Y, Li B, Hu TL, Li T, Zhang Y, Zhang C, Yu M, Wang C, Hou L, Dong Z, Hu TS, Novakovic VA, Shi J. Increased Phosphatidylserine on Blood Cells in Oral Squamous Cell Carcinoma. J Dent Res 2019; 98:763-771. [PMID: 30979345 DOI: 10.1177/0022034519843106] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The specific function of phosphatidylserine (PS) in the context of the development of a hypercoagulable state among individuals with oral squamous cell carcinoma (OSCC) is uncertain. The goal of this study was therefore to assess the exposure of PS on microparticles (MPs) as well as on endothelial and blood cells and to assess procoagulant activity (PCA) as a function of the stage of OSCC progression. We recruited patients with OSCC (n = 63) as well as healthy controls (n = 26) to participate in this study. PS exposure was then assessed via confocal microscopy and flow cytometry, revealing that patients with stage III/IV OSCC exhibited higher frequencies of PS-exposing blood cells, MPs, and serum-cultured endothelial cells (ECs) than did patients with stage I/II OSCC or healthy controls. When we conducted functional coagulation assays, we discovered that PS+ blood cells, MPs, and serum-cultured ECs from patients with stage III/IV OSCC mediated more rapid coagulation and more substantial production of FXa, thrombin, and fibrin as compared with controls. When samples were treated with the PS antagonist lactadherin, this resulted in an 80% disruption of PCA. Strikingly, when pre- and postoperative samples were compared from patients with stage III/IV OSCC undergoing resective surgery, PCA was significantly reduced in the postoperative samples. After stimulating ECs with inflammatory cytokines, we found by confocal microscopy that they expose PS on their cell membranes, thus generating FVa and FXa binding sites and mediating the formation of fibrin. Together our findings provide evidence that PS+ blood cells and MPs are important mediators of the development of a hypercoagulable and prothrombotic state among individuals afflicted by advanced-stage OSCC. As such, a PS blockade may be a viable therapeutic strategy for treating such patients.
Collapse
Affiliation(s)
- Y Liu
- 1 Department of Stomatology, First Hospital, Harbin Medical University, Harbin, China
| | - B Li
- 1 Department of Stomatology, First Hospital, Harbin Medical University, Harbin, China
| | - T L Hu
- 1 Department of Stomatology, First Hospital, Harbin Medical University, Harbin, China.,2 Department of Oral Anatomy and Physiology, Stomatology School, Harbin Medical University, Harbin, China
| | - T Li
- 3 Department of Hematology, First Hospital, Harbin Medical University, Harbin, China
| | - Y Zhang
- 3 Department of Hematology, First Hospital, Harbin Medical University, Harbin, China
| | - C Zhang
- 3 Department of Hematology, First Hospital, Harbin Medical University, Harbin, China
| | - M Yu
- 3 Department of Hematology, First Hospital, Harbin Medical University, Harbin, China
| | - C Wang
- 3 Department of Hematology, First Hospital, Harbin Medical University, Harbin, China
| | - L Hou
- 3 Department of Hematology, First Hospital, Harbin Medical University, Harbin, China
| | - Z Dong
- 4 Department of Cardiology, First Hospital, Harbin Medical University, Harbin, China
| | - T S Hu
- 3 Department of Hematology, First Hospital, Harbin Medical University, Harbin, China
| | - V A Novakovic
- 5 Departments of Research and Surgery, VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - J Shi
- 3 Department of Hematology, First Hospital, Harbin Medical University, Harbin, China.,5 Departments of Research and Surgery, VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
191
|
Han B, Li K, Chu T, Bi M, Zhang H, Yu Y, Shi J, Zhang X, Chen Z, Han C, Bai T. A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
192
|
Pisano CE, Fabia R, Shi J, Wheeler K, Giles S, Ziegfeld S, Stewart D, Flint J, Aguayo P, Alberto E, Burd R, Vitale L, Klein J, Thakkar R. 69 Variation In Acute Resuscitation Among Pediatric 19-A-625-ABA Burn Centers. J Burn Care Res 2019. [DOI: 10.1093/jbcr/irz013.071] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- C E Pisano
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - R Fabia
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - J Shi
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - K Wheeler
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - S Giles
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - S Ziegfeld
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - D Stewart
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - J Flint
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - P Aguayo
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - E Alberto
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - R Burd
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - L Vitale
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - J Klein
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| | - R Thakkar
- Nationwide Children’s Hospital, Columbus, OH; Johns Hopkins Children’s Center, Baltimore, MD; Children’s Mercy Hospitals and Clinics, Kansas City, MO; Children’s National Medical Center, Washington, DC; Children’s Hospital of Michigan, Detroit Medical Center, Detroit, MI
| |
Collapse
|
193
|
Shi J, Zhang ZT. Synthesis, Crystal Structure, and Biological Activity of Two Complexes based on 5-hydroxy-4′-methoxyisoflavone-3′-sulfonate. RUSS J COORD CHEM+ 2019. [DOI: 10.1134/s1070328419030084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
194
|
Yang X, Wang X, Chi M, Zhang M, Shan H, Zhang QH, Zhang J, Shi J, Zhang JZ, Wu RM, Li YL. Osteoprotegerin mediate RANK/RANKL signaling inhibition eases asthma inflammatory reaction by affecting the survival and function of dendritic cells. Allergol Immunopathol (Madr) 2019; 47:179-184. [PMID: 30292447 DOI: 10.1016/j.aller.2018.06.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Revised: 05/22/2018] [Accepted: 06/13/2018] [Indexed: 12/21/2022]
Abstract
INTRODUCTION Asthma is a chronic inflammatory, heterogeneous airway disease affecting millions of people around the world. Dendritic cells (DCs) are considered the most important antigen-presenting cell in asthma airway inflammatory reaction. But whether osteoprotegerin (OPG) mediate RANK/RANKL signaling inhibition influences asthma development by affecting the survival and function of DCs remains unclear. In this study, we assessed the effects of OPG on DCs and asthma. MATERIAL AND METHODS BALB/c mice immunized with ovalbumin (OVA) were challenged thrice with an aerosol of OVA every second day for eight days. Dexamethasone (1.0mg/kg) or OPG (50μg/kg) was administered intraperitoneally to OVA-immunized BALB/c mice on day 24 once a day for nine days. Mice were analyzed for effects of OPG on asthma, inflammatory cell infiltration and cytokine levels in lung tissue. The expression of RANK and β-actin was detected by Western Blot. DCs were isolated from mouse bone morrow. Cell survival was assessed by cell counting. The content of IL-12 was detected by ELISA. RESULTS Results showed that OVA increased the number of inflammatory factors in BALF, elevated lung inflammation scores in mice. OPG reversed the alterations induced by OVA in the asthmatic mice. OPG inhibited the survival and function of DC via inhibition of RANK/RANKL signaling. CONCLUSIONS This research proved inhibition of RANK/RANKL signaling by OPG could ease the inflammatory reaction in asthma, providing new evidence for the application of OPG on asthma.
Collapse
Affiliation(s)
- X Yang
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - X Wang
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - M Chi
- Department of Pediatrics, BaYi Children's Hospital of the PLA Army General Hospital, Beijing, China; The Clinical Medical College of the PLA Army, Second Military Medical University of People's Liberation Army, Shanghai, China
| | - M Zhang
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - H Shan
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Q-H Zhang
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - J Zhang
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - J Shi
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - J-Z Zhang
- Department of Respiratory Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - R-M Wu
- Department of Respiratory Medicine, Shaanxi Provincial People's Hospital, Xi'an, China
| | - Y-L Li
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
| |
Collapse
|
195
|
Zhang Y, Zhang JX, Shi J, Yu Y, Yuan ZF, Lu GZ, Gao Y, Gao YM, Guo XH. [A retrospective analysis of 12 cases of primary thyroid lymphoma]. Beijing Da Xue Xue Bao Yi Xue Ban 2019; 51:165-170. [PMID: 30773562 DOI: 10.19723/j.issn.1671-167x.2019.01.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To discuss the clinical characteristics and diagnostic and therapeutic considerations of primary thyroid lymphoma (PTL) by reviewing PTL cases. METHODS In the study, 12 cases of PTL diagnosed and treated in Peking University First Hospital between January 1995 and September 2015 were identified. The clinical characteristics, management experiences and prognosis of these cases were reviewed retrospectively. RESULTS A total of 12 PTL patients (four males and eight females) were collected, with an average age of 63 years (42 to 81 years) at the time of diagnosis. The average time to clarify diagnosis was 5 months (0.5 to 24 months). Eleven patients presented with a rapidly growing neck mass and visited surgical department, except one complained of coughing and suffocated. Seven patients were hypothyroid, and four were euthyroid at the time of diagnosis. In sonography of 11 cases, nine showed bilateral nodules, with an average diameter of 3.87 cm. Pathologic diagnosis of non-Hodgkin's lymphoma was confirmed in all the 12 cases by means of partial thyroidectomy (four) or core needle biopsy (eight). The pathological subtypes were diffuse large B cell lymphoma in nine patients, mucosa-associated lymphoid tissue lymphoma (MALToma) in two, and small B cell lymphoma in the other one patient. Five patients were concomitant with Hashimoto's thyroiditis. Eleven patients received chemotherapy. Only one patient did not have any further treatment after operation due to an inertia type of tumor. The median overall survival time was 24 months (1-117 months), three patients died. Among the patients who survived, seven completed chemotherapy without disease progression, one MALToma case did not receive chemotherapy after thyroidectomy but was still alive with PTL, and one patient just finished his second course of chemotherapy. CONCLUSION The diagnosis of PTL should be considered when dealing with rapidly growing goiters in elder female Hashimoto's thyroiditis patients whose B ultrasound indicates hypoechogenicity in thyroid nodules or parenchyma, especially with lymphadenopathy and tracheal compressions. Timely use of coreneedle biopsy on suspicious cases can avoid unnecessary surgical trauma, and chemotherapy is the main treatment.
Collapse
Affiliation(s)
- Y Zhang
- Department of Endocrinology, Peking University First Hospital, Beijing 100034, China
| | - J X Zhang
- Department of Pathology, Peking University First Hospital, Beijing 100034, China
| | - J Shi
- Department of Ultrasound, Peking University First Hospital, Beijing 100034, China
| | - Y Yu
- Department of Endocrinology, Peking University First Hospital, Beijing 100034, China
| | - Z F Yuan
- Department of Endocrinology, Peking University First Hospital, Beijing 100034, China
| | - G Z Lu
- Department of Endocrinology, Peking University First Hospital, Beijing 100034, China
| | - Y Gao
- Department of Endocrinology, Peking University First Hospital, Beijing 100034, China
| | - Y M Gao
- Department of Endocrinology, Peking University First Hospital, Beijing 100034, China
| | - X H Guo
- Department of Endocrinology, Peking University First Hospital, Beijing 100034, China
| |
Collapse
|
196
|
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Stover DG, Verschraegen C, Kaklamani V, Wang P, Shi L, Huang W, Shao ZM. Abstract P3-07-07: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-07-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Stover DG, Verschraegen C, Kaklamani V, Wang P, Shi L, Huang W, Shao Z-M. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-07-07.
Collapse
Affiliation(s)
- Y-Z Jiang
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - D Ma
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - C Suo
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - J Shi
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - M Xue
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - DG Stover
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - C Verschraegen
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - V Kaklamani
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - P Wang
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - L Shi
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - W Huang
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - Z-M Shao
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| |
Collapse
|
197
|
Geng C, Li S, Yang S, Shi J, Ding Y, Gao W, Cheng M, Sun Y, Xie Y, Sang M. Abstract P3-01-18: In vivo isolation of circulating tumour cells using CellCollector and detection of gene mutations in different metastasis organ sites in breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-01-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Metastasis is thought to result from tumour cell entry into the circulation and migration to distant organs, where the mutation landscape of metastatic breast cancer (MBC) may shift and vary. The genotypic features of circulating tumour cells (CTCs) typically differ from those of primary breast cancer (BC) cells. Gene mutation analysis of CTCs in MBC may benefit patients by identifying those amenable to specific therapies. Currently, CTCs are primarily isolated in vitro from small volumes of blood. The aim of this study was to isolate CTCs in vivo using CellCollector and screen for specific gene mutations in cells from different metastasis organ sites and molecular subtypes in MBC patients.
Methods: In this study, we used a novel technology, CellCollector, to collect peripheral CTCs. Thirty MBC patients were enrolled, and 17 were analysed with next-generation sequencing (NGS) methods. Clinical characteristics were analysed along with CTC enumeration and detection rates. Whole-genome amplification (WGA) was used to amplify the CTC genomic DNA of 127 genes.
Results: We isolated CTCs in vivo from 20 of 30 MBC patients (66.7%), with a median and mean (range) of 2 (0-15) CTCs. In non-cancer patients, no CTCs were detected. We analysed CTC enumeration and the detection rate in different clinical characteristic subgroups. We found that in their corresponding subgroups, patients younger than 45 years old, with brain metastasis, with three or more metastasis organ sites, or with HER2-positive subtypes had the highest CTC medians and means.As far as clinical characteristics were concerned, the number of CTCs seemed correlated with more advanced clinical characteristics. In the one metastasis organ, two metastasis organs and three or more metastasis organs subgroups, the CTC detection rates were 38.5% (5/13), 77.8% (7/9), and 100.0% (8/8), respectively. The CTC detection rate correlated with the number of metastasis organs; patients with more metastasis organ sites had higher CTC detection rates. We also found that different metastasis organs and molecular subtypes contain high-frequency mutation genes, and also contain unique gene mutations.
Conclusions: In MBC, CellCollector can be used to collect intact CTCs, from which we can obtain gene mutation information. Different metastasis organs and molecular subtypes may have corresponding unique mutations, which may provide a basis for future gene therapy.
CTCs enumeration data and correlations to clinicopathologic characteristicsPatients' characteristics CTCs enumeration RangemedianmeanTotal0-1522Age (years) <450-422≥45 and <600-1512≥600-212Metastatic location Brain0-1556Lung+liver0-712Bone+local recurrence0-411Number of metastatic locations 10-40120-15133-41-723Molecular subtypes Luminal A000Luminal B0-511HER2 positive0-1523Triple negative0-712HER2, human epidermal growth factor receptor 2
Citation Format: Geng C, Li S, Yang S, Shi J, Ding Y, Gao W, Cheng M, Sun Y, Xie Y, Sang M. In vivo isolation of circulating tumour cells using CellCollector and detection of gene mutations in different metastasis organ sites in breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-01-18.
Collapse
Affiliation(s)
- C Geng
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| | - S Li
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| | - S Yang
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| | - J Shi
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| | - Y Ding
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| | - W Gao
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| | - M Cheng
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| | - Y Sun
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| | - Y Xie
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| | - M Sang
- Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China
| |
Collapse
|
198
|
Fan SB, Wang ZJ, Mao Q, Tong CF, Zhai WT, Zheng YZ, Sun CX, Shi J. [Outcomes of splenectomy in relapsed/refractory autoimmune hemolytic anemia]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:132-136. [PMID: 30831628 PMCID: PMC7342661 DOI: 10.3760/cma.j.issn.0253-2727.2019.02.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Indexed: 02/07/2023]
Abstract
Objective: To evaluate the outcomes of splenectomy in the treatment of relapsed/refractory autoimmune hemolytic anemia (AIHA). Methods: Retrospective analysis was performed in 30 cases with relapsed/refractory AIHA who were treated with splenectomy in our hospital. The pre- and post-operative blood routine indexes and responses were followed up. Results: Among the 30 relapsed/refractory AIHA patients, 20 were pure AIHA (including 13 patients with warm antibody AIHA, 2 with warm-cold double antibody AIHA and 5 with Coombs negative AIHA) and 10 were Evans syndrome. The short-term response was evaluated 10-14 days after operation, and the overall response rate (ORR) of short-term response was 90% [12 cases in complete response (CR), 6 cases in partial response (PR)] in 20 therapeutic evaluable cases. Among 13 patients with long-term follow-up data, except 3 patients with Evans syndrome died (2 cases were refractory to splenectomy, 1 case relapsed after surgery), the ORR of 10 patients with relapsed/refractory pure AIHA at 6 months and 12 months were 90% (9/10) and 70% (7/10), respectively, with a median follow-up of 14 (4-156) months. At the end of follow-up, 3 cases had maintained CR for more than 3 years. Conclusion: The short-term response of splenectomy as a second-line treatment for relapsed/refractory AIHA is satisfactory, and long-term outcome of splenectomy is up to 70% at 1 year. Approximately one-third of patients could maintain sustained remission.
Collapse
Affiliation(s)
- S B Fan
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | |
Collapse
|
199
|
Wang Z, Sun X, Shi J, Zheng YZ, Zhao YP. [Clinical features and laboratory data analysis of decreased glycosylated hemoglobin related to hemolytic disease]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:137-140. [PMID: 30831629 PMCID: PMC7342658 DOI: 10.3760/cma.j.issn.0253-2727.2019.02.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/01/2018] [Indexed: 12/03/2022]
Abstract
Objective: To compare the effects of different hemolytic diseases on the level of glycosylated hemoglobin (HbA(1c)) to further explore the relationship between HbA(1c) and laboratory indexes to disclose implications of HbA(1c) in hemolytic diseases. Methods: The distribution of 192 decreased HbA(1c) cases in 4 categories of hemolytic diseases was analyzed. Laboratory indexes related to hemolysis were tested and analyzed in each kind of disease, and relationship between laboratory indexes and HbA(1)c was statistically explored. Results: Diagnoses of decreased HbA(1c) cases mainly included erythrocyte membranopathies (88 cases), immunohemolytic anemia (72 cases), hemoglobinopathy (4 cases) and erythrocyte enzymopathy (5 cases). The distribution of HbA(2) and normal HbF subjects in immunohemolytic anemia and hemoglobinopathy was significantly different from those of HbA(2) and / or abnormal HbF subjects (41.7% vs 22.0%, χ(2)=5.574, P=0.018; 0.7% vs 7.3%, P=0.031). Compared with non-hemolytic disease patients, those who suffered from 4 categories of hemolytic diseases showed lower HbA(1c) level and higher reticulocyte percentage (Ret), indirect bilirubin (IBIL) and free hemoglobin (F-Hb). Different levels of Ret, reticulocyte hemoglobin content (Ret-He), mean corpuscular volume (MCV), IBIL and F-Hb among the 4 kinds of diseases were observed, but the causes of the differences were not the same. HbA(1c) was negatively correlated with other laboratory indexes in erythrocyte membranopathies and immunohemolytic anemia. Conclusions: Hemolytic disease resulted in false lower HbA(1c), but impact of difference on HbA1c between different diseases was not significant. HbA(1c) was closely connected to laboratory indexes related to hemolysis, which might have potential implications for hemolytic diseases such as erythrocyte membranopathies and immunohemolytic anemia.
Collapse
Affiliation(s)
- Z Wang
- Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | | | | | | | | |
Collapse
|
200
|
Ma RJ, Zhu ZM, Yuan XL, Jiang L, Yang SW, Yang J, Guo JM, Shi J, Lei PC, Zhang L, Shang BJ, Sun K, Zhai YP, Li W, Zhang Y. [The analysis of prognosis-associated factors in adults with acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2019; 38:592-596. [PMID: 28810326 PMCID: PMC7342290 DOI: 10.3760/cma.j.issn.0253-2727.2017.07.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
目的 探讨CD34、CD2、CD56表达和FLT3-ITD突变在成人急性早幼粒细胞白血病(APL)中的预后价值。 方法 分析2010年1月至2016年3月确诊的137例成人APL患者的免疫表型及分子学特点,探讨CD34、CD2、CD56表达及FLT3-ITD突变与初诊WBC、完全缓解率、早期死亡率、复发率、总生存(OS)率及无病生存(DFS)率的关系。 结果 ①137例APL患者中,伴CD34表达者占26.3%,伴CD2表达者占25.5%,伴CD56表达者占10.2%,FLT3-ITD突变率为17.5%。CD34、CD2、CD56表达和FLT3-ITD突变在高危组患者中的发生率分别为43.2%、47.7%、18.2%和27.3%;在中/低危组患者中的发生率分别为18.3%、15.1%、6.5%和12.9%,差异均有统计学意义(χ2值分别为9.561、16.764、4.480、4.268,P值分别为0.002、<0.001、0.034、0.039)。②中位随访41个月,完全缓解率为96.9%,早期死亡率为6.6%,复发率为7.3%。与阴性者比较,伴CD34或CD2表达者的复发率增加(18.8%对3.3%,χ2=8.462,P=0.004;16.1%对4.3%,χ2=4.382,P=0.028);伴CD56表达或FLT3-ITD突变者早期死亡率增加(21.4%对4.9%,χ2=5.610,P=0.018;16.7%对4.4%,χ2=4.833,P=0.028)。③137例患者的OS率为88.3%,DFS率为84.7%;CD34、CD56表达或FLT3-ITD突变者的OS及DFS较阴性者差(P值均<0.05)。 结论 在成人APL患者中,CD34、CD2、CD56表达及FLT3-ITD突变是一种不良预后因素。
Collapse
Affiliation(s)
- R J Ma
- Department of Hematology, Henan Provincial People's Hospital, Henan University, Zhengzhou 450003, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|